A pilot, prospective evaluation of a direct thrombin inhibitor, bivalirudin (Angiomax), in patients undergoing lower extremity bypass

Journal of Vascular Surgery

Volumn 52, Issue 2, 2010, Pages 369-374

  Kashyap, Vikram S ^a   Bishop, Paul D ^a   Bena, James F ^a   Rosa, Karen ^a   Sarac, Timur P ^a   Ouriel, Kenneth ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HIRULOG;

AGED; ANASTOMOSIS; ANKLE BRACHIAL INDEX; ANTICOAGULANT THERAPY; ARTERY CLAMP; ARTICLE; ATHEROSCLEROSIS; BLOOD CLOTTING TIME; BLOOD TRANSFUSION; BOLUS INJECTION; BYPASS SURGERY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; HUMAN; OPEN STUDY; OPERATION DURATION; PHASE 3 CLINICAL TRIAL; PILOT STUDY; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; PROSPECTIVE STUDY;

AGED; ANKLE BRACHIAL INDEX; ANTICOAGULANTS; ARTERIAL OCCLUSIVE DISEASES; BLOOD LOSS, SURGICAL; HEMORRHAGE; HIRUDINS; HUMANS; INFUSIONS, INTRAVENOUS; LOWER EXTREMITY; OHIO; PEPTIDE FRAGMENTS; PILOT PROJECTS; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; REOPERATION; SAPHENOUS VEIN; THROMBIN; THROMBOSIS; TIME FACTORS; TREATMENT OUTCOME; VASCULAR PATENCY; VASCULAR SURGICAL PROCEDURES;

EID: 77955517289     PISSN: 07415214     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jvs.2010.02.276     Document Type: Article

References (19)

1. A.T. Hirsch, Z.J. Haskal, N.R. Hertzer, C.W. Bakal, M.A. Creager, and J.L. Halperin ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation Circulation 113 2006 e463 e654
2. J.I. Weitz, M. Hudoba, D. Massel, J. Maraganore, and J. Hirsh Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors J Clin Invest 86 1990 385 391
3. M.A. Mascelli, N.S. Kleiman, S.J. Marciniak Jr, L. Damaraju, H.F. Weisman, and R.E. Jordan Therapeutic heparin concentrations augment platelet reactivity: implications for the pharmacologic assessment of the glycoprotein IIb/IIIa antagonist abciximab Am Heart J 139 2000 696 703
4. Z. Xiao, and P. Theroux Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor Circulation 97 1998 251 256
5. E. Young, M. Prins, M.N. Levine, and J. Hirsh Heparin binding to plasma proteins, an important mechanism for heparin resistance Thromb Haemost 67 1992 639 643
6. T.E. Warkentin, A. Greinacher, A. Koster, and A.M. Lincoff Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest 133 6 Suppl 2008 340S 380S
7. J.G. Calaitges, T.K. Liem, D. Spadone, W.K. Nichols, and D. Silver The role of heparin-associated antiplatelet antibodies in the outcome of arterial reconstruction J Vasc Surg 29 1999 779 785
8. C. Kearon, and J. Hirsh Management of anticoagulation before and after elective surgery N Engl J Med 336 1997 1506 1511
9. C.P. Semba, T.P. Murphy, C.W. Bakal, K.A. Calis, T.A. Matalon The Advisory Panel Thrombolytic therapy with use of alteplase (rt-PA) in peripheral arterial occlusive disease: review of the clinical literature J Vasc Interv Radiol 11 2 Pt 1 2000 149 161
10. H.D. White Pharmacological and clinical profile of bivalirudin in the treatment of patients with acute coronary syndrome Expert Opin Drug Metab Toxicol 5 2009 529 538
11. A.K. Rao, C. Pratt, A. Berke, A. Jaffe, I. Ockene, and T.L. Schreiber Thrombolysis in Myocardial Infarction (TIMI) Trialphase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase J Am Coll Cardiol 11 1988 1 11
12. S.M. Bates, and J.I. Weitz Direct thrombin inhibitors for treatment of arterial thrombosis: potential differences between bivalirudin and hirudin Am J Cardiol 82 1998 12P 18P
13. R.B. Eslam, N. Reiter, A. Kaider, S. Eichinger, I.M. Lang, and S. Panzer Regulation of PAR-1 in patients undergoing percutaneous coronary intervention: effects of unfractionated heparin and bivalirudin Eur Heart J 30 2009 1831 1836
14. J.A. Bittl, B.R. Chaitman, F. Feit, W. Kimball, and E.J. Topol Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: Final report reanalysis of the Bivalirudin Angioplasty Study Am Heart J 142 2001 952 959
15. A.M. Lincoff, J.A. Bittl, R.A. Harrington, F. Feit, N.S. Kleiman, and J.D. Jackman Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial JAMA 289 2003 853 863
16. A.M. Lincoff, N.S. Kleiman, D.J. Kereiakes, F. Feit, J.A. Bittl, and J.D. Jackman Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial JAMA 292 2004 696 703
17. D.E. Allie, P. Hall, N.W. Shammas, R. Safian, J.R. Laird, and J.J. Young The Angiomax Peripheral Procedure Registry of Vascular Events Trial (APPROVE): in-hospital and 30-day results J Invasive Cardiol 16 2004 651 656
18. N.G. Smedira, C.M. Dyke, A. Koster, M. Jurmann, D.S. Bhatia, and T. Hu Anticoagulation with bivalirudin for off-pump coronary artery bypass grafting: the results of the EVOLUTION-OFF study J Thorac Cardiovasc Surg 131 2006 686 692
19. C.M. Dyke, N.G. Smedira, A. Koster, S. Aronson, H.L. McCarthy, and R. Kirshner A comparison of bivalirudin to heparin with protamine reversal in patients undergoing cardiac surgery with cardiopulmonary bypass: the EVOLUTION-ON study J Thorac Cardiovasc Surg 131 2006 533 539